We hypothesize that CD74 and RPL26L1 serve as dual diagnostic biomarkers and functionally contribute to disease pathophysiology, making them compelling candidates for therapeutic targeting in OSA-MDD comorbidity. This evidence concerns the gene CD74 and obstructive sleep apnea syndrome.